Clinical Trials
678 trialsDose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
REVIVE
University of Chicago
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Roswell Park Cancer Institute
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
N01-A-PICIT-GT
Peking University People's Hospital
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
Safety of Lung Cryobiopsy in People With Cancer
Memorial Sloan Kettering Cancer Center
NIVIPI-Brain
Fundación GECP
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
AxeCan
HealthPartners Institute
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
ALPINE 2
Technische Universität Dresden
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Samsung Medical Center
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
PEERS
Fundación GECP
MERIT-lung
Fundación GECP
OPTALK
Groupe Francais De Pneumo-Cancerologie
SFRT-IM-P2
Tianjin Medical University Cancer Institute and Hospital
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Shanghai Chest Hospital
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
NIBCUN
Sun Yat-sen University
NUMER
Sun Yat-sen University
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
LCNEC-ALPINE
Technische Universität Dresden
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mayo Clinic
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
Case Comprehensive Cancer Center
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
University of Washington
358
Brown University
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
DEFLECT I
University Medical Center Groningen
SMILE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
GAPIMET
University of Zurich